Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) FCF Margin (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed FCF Margin for 11 consecutive years, with 301.56% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin rose 36177.0% to 301.56% in Q4 2025 year-over-year; TTM through Dec 2025 was 584.98%, a 1881.0% increase, with the full-year FY2025 number at 584.98%, up 1881.0% from a year prior.
  • FCF Margin was 301.56% for Q4 2025 at Intellia Therapeutics, up from 558.18% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 5502.71% in Q4 2023 to a low of 24313.67% in Q3 2021.
  • A 5-year average of 1559.39% and a median of 700.84% in 2023 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: crashed -2418200bps in 2021, then surged 2374607bps in 2022.
  • Intellia Therapeutics' FCF Margin stood at 447.48% in 2021, then crashed by -47bps to 658.01% in 2022, then soared by 936bps to 5502.71% in 2023, then plummeted by -112bps to 663.34% in 2024, then surged by 55bps to 301.56% in 2025.
  • Per Business Quant, the three most recent readings for NTLA's FCF Margin are 301.56% (Q4 2025), 558.18% (Q3 2025), and 705.61% (Q2 2025).